PMID- 27798875
OWN - NLM
STAT- MEDLINE
DCOM- 20170127
LR  - 20181202
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 10
DP  - 2016 Oct
TI  - Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem 
      Cells and Reverses Chemoresistance.
PG  - 5153-5161
AB  - BACKGROUND: There is a growing interest in repurposing antipsychotic dopamine 
      antagonists for cancer treatment; however, antipsychotics are often associated 
      with an increased risk of fatal events. The anticancer activities of 
      aripiprazole, an antipsychotic drug with partial dopamine agonist activity and an 
      excellent safety profile, remain unknown. MATERIALS AND METHODS: The effects of 
      aripiprazole alone or in combination with chemotherapeutic agents on the growth, 
      sphere-forming ability and stem cell/differentiation/chemoresistance marker 
      expression of cancer stem cells, serum-cultured cancer cells from which they were 
      derived, and normal cells were examined. RESULTS: At concentrations non-toxic to 
      normal cells, aripiprazole inhibited the growth of serum-cultured cancer cells 
      and cancer stem cells. Furthermore, aripiprazole induced differentiation and 
      inhibited sphere formation, as well as stem cell marker expression of cancer stem 
      cells while inhibiting their survivin expression and sensitizing them to 
      chemotherapeutic agents. CONCLUSION: Repurposing aripiprazole as an anticancer 
      stem cell drug may merit further consideration.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Suzuki, Shuhei
AU  - Suzuki S
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
AD  - Department of Clinical Oncology, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Okada, Masashi
AU  - Okada M
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan m-okada@med.id.yamagata-u.ac.jp ckitanak@med.id.yamagata-u.ac.jp.
FAU - Kuramoto, Kenta
AU  - Kuramoto K
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Takeda, Hiroyuki
AU  - Takeda H
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
AD  - Department of Clinical Oncology, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Sakaki, Hirotsugu
AU  - Sakaki H
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
AD  - Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Watarai, Hikaru
AU  - Watarai H
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
AD  - Second Department of Surgery, Yamagata University School of Medicine, Yamagata, 
      Japan.
FAU - Sanomachi, Tomomi
AU  - Sanomachi T
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Seino, Shizuka
AU  - Seino S
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan.
AD  - Research Institute for Promotion of Medical Sciences, Yamagata University Faculty 
      of Medicine, Yamagata, Japan.
FAU - Yoshioka, Takashi
AU  - Yoshioka T
AD  - Department of Clinical Oncology, Yamagata University School of Medicine, 
      Yamagata, Japan.
FAU - Kitanaka, Chifumi
AU  - Kitanaka C
AD  - Department of Molecular Cancer Science, Yamagata University School of Medicine, 
      Yamagata, Japan m-okada@med.id.yamagata-u.ac.jp ckitanak@med.id.yamagata-u.ac.jp.
AD  - Research Institute for Promotion of Medical Sciences, Yamagata University Faculty 
      of Medicine, Yamagata, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Survivin)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Antipsychotic Agents/pharmacology
MH  - Aripiprazole/*pharmacology
MH  - Cell Differentiation/drug effects
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Dopamine Agonists/pharmacology
MH  - Drug Repositioning
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Fibroblasts/drug effects
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/metabolism
MH  - Neoplastic Stem Cells/*drug effects
MH  - Neural Stem Cells/drug effects
MH  - Rats
MH  - Survivin
OTO - NOTNLM
OT  - Drug repositioning
OT  - chemotherapy
OT  - drug resistance
OT  - mental illnesses
OT  - psychiatric disorders
OT  - self-renewal capacity
EDAT- 2016/11/01 06:00
MHDA- 2017/01/28 06:00
CRDT- 2016/11/01 06:00
PHST- 2016/09/14 00:00 [received]
PHST- 2016/09/27 00:00 [accepted]
PHST- 2016/11/01 06:00 [pubmed]
PHST- 2017/01/28 06:00 [medline]
PHST- 2016/11/01 06:00 [entrez]
AID - 36/10/5153 [pii]
AID - 10.21873/anticanres.11085 [doi]
PST - ppublish
SO  - Anticancer Res. 2016 Oct;36(10):5153-5161. doi: 10.21873/anticanres.11085.